CDMOs offering Sterile Fill-Finish & Aseptic Manufacturing with Gene Therapy

Matching companies

• AGC Biologics

  Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.

• Aldevron

  Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.

• Ascend

  Ascend is a gene-to-GMP development partner specializing in advanced biologics and vaccines with 60+ years of custom biologics expertise and 20+ years of AAV development capability. The company offers onsite fill-finish capabilities across multiple US locations and combines next-generation technologies with deep regulatory acumen.

• Ascendia Pharmaceutical Solutions

  Specialty CDMO offering formulation development, analytical services, and cGMP manufacturing for small molecules and biologics from preclinical through Phase 1 and commercialization.

• Catalent

  Leading global CDMO offering end-to-end development and manufacturing for pharma, biotech, and consumer health—spanning oral dose, biologics, cell and gene therapies, clinical supply, and specialty formulations with advanced technologies and worldwide GMP capacity.

• Charles River Cell & Gene Therapy

  Charles River provides discovery, development, and manufacturing services across the drug development continuum, including cell and gene therapy capabilities.

• FUJIFILM Biotechnologies

  CDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.

• Forge Biologics

  Dedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance.

• National Resilience

  End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.

• Oxford Biomedica

  Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.

• Patheon (Thermo Fisher Pharma Services)

  Patheon is a trusted global contract development and manufacturing organization (CDMO) partner owned by Thermo Fisher Scientific, offering 360° integrated solutions from early-stage R&D through clinical supply and commercial manufacturing.

• Pharmaron

  Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.

• Siegfried Holding

  Global CDMO with 16 production sites across four continents, offering integrated development and manufacturing from early-phase to commercial scale for drug substance and drug product.

• Syngene International

  Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.